MNKD Q3 2022 Earnings — MannKind Corporation Revenue & Financial Results | Market Cap Arena

MNKDMannKind Corporation

$813M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+47.8% YoY

Gross Profit

$15M46.8% margin

Operating Income

-$10M-29.3% margin

Net Income

-$14M-44.0% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+73.7%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$294M

Total Liabilities

$532M

Stockholders' Equity

-$238M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$22M	+47.8%
Gross Profit	$15M	$12M	+24.7%
Operating Income	-$10M	-$7M	-45.8%
Net Income	-$14M	-$4M	-226.1%

Revenue Segments

Product Sales

$26M53%

Product

$16M33%

Royalty

$6M13%

Service

$430,0001%